Global Information
회사소개 | 문의 | 위시리스트

람베르트 이튼 근무력 증후군(LEMS) : 시장 인사이트, 역학, 시장 예측(-2028년)

Lambert-Eaton Myasthenic Syndrome (LEMS) - Market Insights, Epidemiology, and Market Forecast-2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 08월 상품 코드 905931
페이지 정보 영문 154 Pages
가격
US $ 6,250 ₩ 7,591,000 PDF by E-mail (Single User License)
US $ 12,500 ₩ 15,182,000 PDF by E-mail (Site License)
US $ 18,750 ₩ 22,773,000 PDF by E-mail (Global License)


람베르트 이튼 근무력 증후군(LEMS) : 시장 인사이트, 역학, 시장 예측(-2028년) Lambert-Eaton Myasthenic Syndrome (LEMS) - Market Insights, Epidemiology, and Market Forecast-2028
발행일 : 2019년 08월 페이지 정보 : 영문 154 Pages

세계의 람베르트 이튼 근무력 증후군(LEMS: Lambert-Eaton Myasthenic Syndrome) 시장에 대해 조사했으며, 시장 점유율, 주요 7개국 역학 및 시장 전망, 주요 기업 개요, 시장 성장 촉진요인 등의 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 보고서 소개

제3장 시장 개요

  • 시장 점유율(%) 2017년 분포
  • 시장 점유율(%) 2028년 분포

제4장 람베르트 이튼 근무력 증후군(LEMS) : 질환 개요

  • 서론
  • 징후 및 증상
  • 원인
  • 위험인자
  • 병태생리
  • 병인
  • 임상증상
  • 진단
    • 진단 알고리즘

제5장 역학 및 환자 인구

  • 주요 조사결과
  • 주요 7개국에서의 유행 사례
  • 주요 7개국에서 진단된 일반적인 사례
  • 주요 7개국에서 진단된 일반적인 사례 : 성별
  • 주요 7개국에서 진단된 일반적인 사례 : 종류별

제6장 미국 역학

제7장 유럽 5개국 역학

  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국

제8장 일본 역학

제9장 치료

  • 치료 가이드라인
    • 람베르트 이튼 근무력 증후군(LEMS) 관리에 관한 이탈리아의 추천사항
    • EFNS 가이드라인 : 자기면역성 신경관계 전달 장애 치료 가이드라인

제10장 잠재적 수요

제11장 시판약

  • Firdapse : Catalyst Pharmaceutical
    • 제품 설명
    • 기타 발달 활동
    • 임상 개발
    • 임상시험 정보
    • 안전성 및 유효성
    • 제품 개요

제12장 Ruzurgi : Jacobus Pharmaceutical Company Inc.

    • 제품 설명
    • 기타 개발 활동
    • 임상 개발
    • 임상시험 정보
    • 안전성 및 유효성
    • 제품 개요

제13장 람베르트 이튼 근무력 증후군 : 주요 7개국 시장 분석

  • 주요 조사결과
  • 주요 7개국 시장 규모(기본 사례 시나리오)
  • 주요 7개국의 치료법별 시장 규모(기본 사례 시나리오)
  • 주요 7개국 시장 규모(부정적 시나리오)
  • 주요 7개국의 치료법별 시장 규모(부정적 시나리오)

제14장 시장 전망 : 미국

제15장 시장 전망 : 유럽

  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국

제16장 시장 전망 : 일본

제17장 시장 성장 촉진요인

제18장 시장 성장 저해요인

제19장 부록

  • 보고 방법

제20장 DelveInsight의 서비스 내용

제21장 면책사항

LSH 19.08.14

List of Tables

  • Table 1 Signs and Symptoms of LEMS
  • Table 2 Classification and characteristics of voltage-gated calcium channels (VGCC)
  • Table 3 Total Prevalent Cases of LEMS in 7MM (2017-2028)
  • Table 4 Total Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Table 5 Gender-Specific Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Table 6 Type-Specific Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Table 7 Total Prevalent Cases of LEMS in the United States (2017-2028)
  • Table 8 Total Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Table 9 Gender Specific Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Table 10 Type Specific Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Table 11 Diagnosed Prevalent Cases of LEMS by Malignancy in the United States (2017-2028)
  • Table 12 Total Prevalent Cases of LEMS in Germany (2017-2028)
  • Table 13 Total Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Table 14 Gender Specific Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Table 15 Type Specific Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Table 16 Diagnosed Prevalent Cases of LEMS by Malignancy in Germany (2017-2028)
  • Table 17 Total Prevalent Cases of LEMS in France (2017-2028)
  • Table 18 Total Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Table 19 Gender Specific Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Table 20 Type Specific Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Table 21 Diagnosed Prevalent Cases of LEMS by Malignancy in France (2017-2028)
  • Table 22 Total Prevalent Cases of LEMS in Italy (2017-2028)
  • Table 23 Total Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Table 24 Gender Specific Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Table 25 Type Specific Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Table 26 Diagnosed Prevalent Cases of LEMS by Malignancy in Italy (2017-2028)
  • Table 27 Total Prevalent Cases of LEMS in Spain (2017-2028)
  • Table 28 Total Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Table 29 Gender Specific Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Table 30 Type Specific Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Table 31 Diagnosed Prevalent Cases of LEMS by Malignancy in Spain (2017-2028)
  • Table 32 Total Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Table 33 Total Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Table 34 Gender Specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Table 35 Type Specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Table 36 Diagnosed Prevalent Cases of LEMS by Malignancy in the United Kingdom (2017-2028)
  • Table 37 Total Prevalent Cases of LEMS in Japan (2017-2028)
  • Table 38 Total Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Table 39 Gender Specific Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Table 40 Type Specific Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Table 41 Diagnosed Prevalent Cases of LEMS by Malignancy in Japan (2017-2028)
  • Table 42 Firdapse, Clinical Trial Description, 2019
  • Table 43 Ruzurgi, Clinical Trial Description, 2019
  • Table 44 Market Size of Lambert-Eaton Myasthenic Syndrome in 7MM (With Base Case Scenario) in USD Million (2017-2028)
  • Table 45 Market Size of LEMS by Therapies in 7MM in USD Million (2017-2028)
  • Table 46 Market Size of Lambert-Eaton Myasthenic Syndrome in 7MM (With Downside Scenario) in USD Million (2017-2028)
  • Table 47 Market Size of LEMS by Therapies in 7MM in USD Million (2017-2028)
  • Table 48 United States Market Size of LEMS (With Base Case Scenario) in USD Million (2017-2028)
  • Table 49 Market Size of LEMS by Therapies in the United States (With Base Case Scenario) in USD Million (2017-2028)
  • Table 50 United States Market Size of LEMS (With Downside Scenario) in USD Million (2017-2028)
  • Table 51 Market Size of LEMS by Therapies in the United States (With Downside Scenario) in USD Million (2017-2028)
  • Table 52 Germany Market Size of LEMS in USD Million (2017-2028)
  • Table 53 Germany Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Table 54 France Market Size of LEMS in USD Million (2017-2028)
  • Table 55 France Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Table 56 Italy Market Size of LEMS in USD Million (2017-2028)
  • Table 57 Italy Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Table 58 Spain Market Size of LEMS in USD Million (2017-2028)
  • Table 59 Spain Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Table 60 United Kingdom Market Size of LEMS in USD Million (2017-2028)
  • Table 61 United Kingdom Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Table 62 Japan Market Size of LEMS in USD Million (2017-2028)
  • Table 63 Japan Market Size of LEMS by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1 Signs and Symptoms of LEMS
  • Figure 2 Lambert and colleague's classical description of the clinical features
  • Figure 3 Mechanism of Action
  • Figure 4 Pathophysiology of LEMS and effects of symptomatic treatment
  • Figure 5 Diagnostic Algorithm
  • Figure 6 LEMS diagnosis and oncological screening algorithm
  • Figure 7 Diagnostic Algorithm of LEMS
  • Figure 8 Diagnostic algorithm for clinically suspected LEMS
  • Figure 9 Total Prevalent Cases of LEMS in 7MM (2017-2028)
  • Figure 10 Total Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Figure 11 Gender-Specific Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Figure 12 Type-Specific Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Figure 13 Total Prevalent Cases of LEMS in the United States (2017-2028)
  • Figure 14 Total Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Figure 15 Gender Specific Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Figure 16 Type Specific Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Figure 17 Diagnosed Prevalent Cases of LEMS by Malignancy in the United States (2017-2028)
  • Figure 18 Total Prevalent Cases of LEMS in Germany (2017-2028)
  • Figure 19 Total Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Figure 20 Gender Specific Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Figure 21 Type Specific Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Figure 22 Diagnosed Prevalent Cases of LEMS by Malignancy in Germany (2017-2028)
  • Figure 23 Total Prevalent Cases of LEMS in France (2017-2028)
  • Figure 24 Total Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Figure 25 Gender Specific Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Figure 26 Type Specific Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Figure 27 Diagnosed Prevalent Cases of LEMS by Malignancy in France (2017-2028)
  • Figure 28 Total Prevalent Cases of LEMS in Italy (2017-2028)
  • Figure 29 Total Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Figure 30 Gender Specific Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Figure 31 Type Specific Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Figure 32 Diagnosed Prevalent Cases of LEMS by Malignancy in Italy (2017-2028)
  • Figure 33 Total Prevalent Cases of LEMS in Spain (2017-2028)
  • Figure 34 Total Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Figure 35 Gender Specific Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Figure 36 Type Specific Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Figure 37 Diagnosed Prevalent Cases of LEMS by Malignancy in Spain (2017-2028)
  • Figure 38 Total Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Figure 39 Total Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Figure 40 Gender Specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Figure 41 Type Specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Figure 42 Diagnosed Prevalent Cases of LEMS by Malignancy in the United Kingdom (2017-2028)
  • Figure 43 Total Prevalent Cases of LEMS in Japan (2017-2028)
  • Figure 44 Total Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Figure 45 Gender Specific Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Figure 46 Type Specific Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Figure 47 Diagnosed Prevalent Cases of LEMS by Malignancy in Japan (2017-2028)
  • Figure 48 Treatment Algorithm
  • Figure 49 Flowchart of recommended screening for SCLC in patients with LEMS
  • Figure 50 Treatment Algorithm
  • Figure 51 Unmet Needs
  • Figure 52 Market Size of Lambert-Eaton Myasthenic Syndrome (LEMS) in the 7MM (With Base Case Scenario) in USD Million (2017-2028)
  • Figure 53 Market Size of LEMS by therapies in the 7MM, in USD Million (2017-2028)
  • Figure 54 Market Size of Lambert-Eaton Myasthenic Syndrome (LEMS) in the 7MM (With Downside Scenario) in USD Million (2017-2028)
  • Figure 55 Market Size of LEMS by therapies in the 7MM, in USD Million (2017-2028)
  • Figure 56 United States Market Size of LEMS (With Base Case Scenario) in USD Million (2017-2028)
  • Figure 57 United States Market Size of LEMS by Therapies (With Base Case Scenario) in USD Million (2017-2028)
  • Figure 58 United States Market Size of LEMS (With Downside Scenario) in USD Million (2017-2028)
  • Figure 59 United States Market Size of LEMS (With Downside Scenario) by Therapies in USD Million (2017-2028)
  • Figure 60 Germany Market Size of LEMS in USD Million (2017-2028)
  • Figure 61 Germany Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Figure 62 France Market Size of LEMS in USD Million (2017-2028)
  • Figure 63 France Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Figure 64 Italy Market Size of LEMS in USD Million (2017-2028)
  • Figure 65 Italy Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Figure 66 Spain Market Size of LEMS in USD Million (2017-2028)
  • Figure 67 Spain Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Figure 68 United Kingdom Market Size of LEMS in USD Million (2017-2028)
  • Figure 69 United Kingdom Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Figure 70 Japan Market Size of LEMS in USD Million (2017-2028)
  • Figure 71 Japan Market Size of LEMS by Therapies in USD Million (2017-2028)
  • Figure 72 Market Drivers
  • Figure 73 Market Barriers

DelveInsight's 'Lambert-Eaton Myasthenic Syndrome (LEMS) - Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of LEMS in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Lambert-Eaton Myasthenic Syndrome (LEMS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Lambert-Eaton Myasthenic Syndrome (LEMS) - Disease Understanding and Treatment Algorithm

The DelveInsight Lambert-Eaton Myasthenic Syndrome (LEMS) market report gives a thorough understanding of the Lambert-Eaton Myasthenic Syndrome (LEMS) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Lambert-Eaton Myasthenic Syndrome (LEMS) in the US, Europe, and Japan.

Lambert-Eaton Myasthenic Syndrome (LEMS)

The Lambert-Eaton Myasthenic Syndrome (LEMS) epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM, Total Diagnosed Prevalence of LEMS in 7MM, Gender-specific Diagnosed Prevalence of LEMS, Type-specific Diagnosed Prevalence of LEMS, and Diagnosed Prevalence of LEMS by malignancy) scenario of Lambert-Eaton Myasthenic Syndrome (LEMS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of diagnosed prevalent population of Lambert-Eaton Myasthenic Syndrome (LEMS) was found to be 3,349, in 7MM in the year 2017.

Lambert-Eaton Myasthenic Syndrome (LEMS) Drug Chapters

This segment of the Lambert-Eaton Myasthenic Syndrome (LEMS) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently, there is no cure of LEMS disease and the present treatments provide symptomatic support. Medications and therapies that may be used to treat Lambert-Eaton myasthenic syndrome include: 3, 4-diaminopyridine (enhances acetylcholine release), anticholinesterase agents (e.g., Pyridostigmine), plasma exchange (where blood plasma is removed and replaced with fluid, protein, or donated plasma), intravenous immunoglobulins (IVIG), and medications that suppress the immune system (e.g., prednisone, azathioprine). The first choice for symptomatic treatment of patients with LEMS is 3, 4-diaminopyridine. For patients with refractory weakness, immunosuppression with IVIG as the first-line agent is recommended.

Till now, there are only two FDA approved therapies present in the market. Firdapse is a FDA approved therapy of LEMS in adults, while another drug i.e. Ruzurgi is approved for pediatric patients. Before the approval of Ruzurgi, the market was totally dominated by Firdapse, since it was the only approved therapies, but after the approval of Ruzurgi, it is expected that it will cover the market share of Firdapse because of its less cost. Soon after the approval of Ruzurgi, Catalyst Pharma filed a lawsuit against the US FDA and several related parties challenging the recent approval of a new drug application and related drug labeling for Jacobus Pharmaceutical Company's drug Ruzurgi. Because of the filed lawsuit the market of LEMS is segmented into two categories i.e. with base scenario (if Ruzurgi did not get approval) and with downside scenario (if Ruzurgi get approval).

Lambert-Eaton Myasthenic Syndrome (LEMS) Market Outlook

The Lambert-Eaton Myasthenic Syndrome (LEMS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM was found to be USD 56.75 million in 2017 and is expected to increase at a CAGR of XX% from 2017-2028.

Lambert-Eaton Myasthenic Syndrome (LEMS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lambert-Eaton Myasthenic Syndrome (LEMS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Lambert-Eaton Myasthenic Syndrome (LEMS) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Lambert-Eaton Myasthenic Syndrome (LEMS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Lambert-Eaton Myasthenic Syndrome (LEMS) Infections market
  • Organize sales and marketing efforts by identifying the best opportunities for Lambert-Eaton Myasthenic Syndrome (LEMS) market
  • To understand the future market competition in the Lambert-Eaton Myasthenic Syndrome (LEMS) market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Lambert-Eaton Myasthenic Syndrome (LEMS): Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of LEMS in 2017
  • 3.2. Market Share (%) Distribution of LEMS in 2028

4. Lambert-Eaton Myasthenic Syndrome (LEMS): Disease Overview

  • 4.1. Introduction
  • 4.2. Signs and Symptoms
  • 4.3. Cause of Lambert-Eaton Myasthenic Syndrome
  • 4.4. Risk Factors
  • 4.5. Pathophysiology Lambert-Eaton Myasthenic Syndrome
  • 4.6. Pathogenesis
  • 4.7. Clinical Manifestations
  • 4.8. Diagnosis
    • 4.8.1. Diagnostic Algorithm

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM
  • 5.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM
  • 5.4. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM
  • 5.5. Type-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM

6. United States Epidemiology

  • 6.1. Assumptions and Rationale
  • 6.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
  • 6.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
  • 6.4. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
  • 6.5. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
  • 6.6. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in the United States

7. EU-5 Epidemiology

  • 7.1. Germany
    • 7.1.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
    • 7.1.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
    • 7.1.3. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
    • 7.1.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
    • 7.1.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Germany
  • 7.2. France
    • 7.2.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
    • 7.2.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
    • 7.2.3. Gender-Specific Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
    • 7.2.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
    • 7.2.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in France
  • 7.3. Italy
    • 7.3.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
    • 7.3.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
    • 7.3.3. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
    • 7.3.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
    • 7.3.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Italy
  • 7.4. Spain
    • 7.4.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
    • 7.4.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
    • 7.4.3. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
    • 7.4.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
    • 7.4.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Spain
  • 7.5. United Kingdom
    • 7.5.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
    • 7.5.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
    • 7.5.3. Gender Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
    • 7.5.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
    • 7.5.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in the United Kingdom

8. Japan Epidemiology

  • 8.1. Assumptions and Rationale
  • 8.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
  • 8.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
  • 8.4. Gender Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
  • 8.5. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
  • 8.6. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Japan

9. Treatment

  • 9.1. Treatment Guidelines
    • 9.1.1. Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management
    • 9.1.2. EFNS Guidelines: Guidelines for treatment of autoimmune neuromuscular transmission disorders

10. Unmet Needs

11. Marketed Drugs

  • 11.1. Firdapse: Catalyst Pharmaceutical
    • 11.1.1. Product Description
    • 11.1.2. Other Developmental Activities
    • 11.1.3. Clinical Development
    • 11.1.4. Clinical Trials Information
    • 11.1.5. Safety and Efficacy
    • 11.1.6. Product Profile

12. Ruzurgi: Jacobus Pharmaceutical Company Inc.

    • 12.1.1. Product Description
    • 12.1.2. Other Developmental Activities
    • 12.1.3. Clinical Development
    • 12.1.4. Clinical Trials Information
    • 12.1.5. Safety and Efficacy
    • 12.1.6. Product Profile

13. Lambert-Eaton Myasthenic Syndrome (LEMS): 7MM Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM (With Base Case Scenario)
  • 13.3. Market Size of LEMS by Therapies in the 7MM (With Base Case Scenario)
  • 13.4. Market Size of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM (With Downside Scenario)
  • 13.5. Market Size of LEMS by Therapies in the 7MM (With Downside Scenario)

14. Market Outlook: The United States

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of Lambert-Eaton Myasthenic Syndrome (With Base Case Scenario)
    • 14.1.2. Lambert-Eaton Myasthenic Syndrome Market by Therapies (With Base Case Scenario)
    • 14.1.3. Total Market size of Lambert-Eaton Myasthenic Syndrome (With Downside Scenario)
    • 14.1.4. Lambert-Eaton Myasthenic Syndrome Market by Therapies (With Downside Scenario)

15. Market Outlook: Europe

  • 15.1. Germany
    • 15.1.1. Total Market size of Lambert-Eaton Myasthenic Syndrome (LEMS)
    • 15.1.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Market by Therapies
  • 15.2. France
    • 15.2.1. Total Market size of Lambert-Eaton Myasthenic Syndrome (LEMS)
    • 15.2.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Market by Therapies
  • 15.3. Italy
    • 15.3.1. Total Market size of Lambert-Eaton Myasthenic Syndrome (LEMS)
    • 15.3.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Market by Therapies
  • 15.4. Spain
    • 15.4.1. Total Market size of Lambert-Eaton Myasthenic Syndrome (LEMS)
    • 15.4.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Market by Therapies
  • 15.5. United Kingdom
    • 15.5.1. Total Market size of Lambert-Eaton Myasthenic Syndrome (LEMS)
    • 15.5.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Market by Therapies

16. Market Outlook: Japan

  • 16.1. Total Market size of Lambert-Eaton Myasthenic Syndrome (LEMS)
  • 16.2. Lambert-Eaton Myasthenic Syndrome (LEMS) Market by Therapies

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

Back to Top
전화 문의
F A Q